News

The publication reported that those behind the pioneering facility are claiming that it will revolutionize the way that chemicals used in commonplace products are manufactured. The bdaily website

According to Arpida, the results of the second trial, called ASSIST-2, (Arpida’s Skin and Skin Structure Infection STudies), validated the results of the first phase of testing, ASSIST-1.

In a press release regarding the decision to suspend the development of valopicitabine, Idenix said that it was disappointed with the FDA’s decision, and that the company would

The company said that the drug, currently named V3381, was generally well-tolerated and that the data showed that further clinical development was warranted. V3381 is a novel drug

The legal case was brought against Orphan Medical Inc, a subsidiary of Jazz Pharmaceuticals. Orphan Medical pled guilty to one count of felony misbranding of a pharmaceutical product.

prGCD is a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher disease, a lysosomal storage disorder in humans. The phase III

The trial, an open-label Phase III study of Erbitux plus a taxane and carboplatin in the first-line treatment for metastatic non-small cell lung cancer (NSCLC), did not meet

The primary objective of the chronic toxicology studies is to assess the safety of R7128 when given for six months. Roche triggered a $7.5 million milestone payment to

Up to 138 (92 orBec and 46 placebo) patients will be enrolled. The primary endpoint of the trial is the proportion of subjects who develop acute GVHD with